One day after President Donald Trump’s long-anticipated executive order directing federal authorities to reclassify cannabis as a less dangerous drug, the $32 billion legal U.S. cannabis industry is posing a central question: When?
Trump’s order instructs Attorney General Pam Bondi to reschedule marijuana “in the most expeditious manner in accordance” with federal law. But on the quickest realistic timeline, it could still be months before the promised benefits for research and tax relief appear, legal experts told MJBizDaily.
“I wish I could give you something like an exact number, but there’s just way too much discretion here,” said Matthew Cavedon, the director of the Project on Criminal Justice at the Cato Institute, a Washington, D.C.-based libertarian think tank.
“I can’t say exactly how long that will take because there is no deadline,” added Shane Pennington, a prominent administrative law expert and partner at Blank Rome.
Still, there is some idea at least of the bureaucratic and legal processes to be followed. And at least some credit is owed to former President Joe Biden, who launched the initial cannabis reform process that Trump moved along Thursday.
However, if any steps are skipped or corners cut, there are significant risks that could delay rescheduling entirely, legal experts warn.
‘No deadline’ for marijuana to be rescheduled
Pennington represented interested parties in the marijuana rescheduling hearings before a U.S. Drug Enforcement Administration law judge that were paused on the eve of Trump’s inauguration.
Those hearings were part of the marijuana rescheduling process begun under Biden in October 2022.
Trump’s process built on that by recognizing the August 2023 Health and Human Services finding that cannabis has a currently accepted medical use in the U.S.
However, Trump went further than Biden and directed agencies to make the change rather than simply review federal policy.
Nonetheless, “The issue is, they’re going to have a bureaucratic gauntlet to run,” Pennington said.
In theory, Bondi could cancel the hearings – rendering an appeal of the hearings brought moot – and publish a final rule in the Federal Register reclassifying cannabis a Schedule 3 drug in five days.
“Five days, not business days,” Pennington said.
Lawsuits challenging marijuana rescheduling are guaranteed
But once Bondi does that, there’s another hurdle to clear: the courts.
Supports have long expected lawsuits challenging the final rule.
Smart Approaches to Marijuana, a prominent legalization foe that challenged the Biden administration process, has already retained former Attorney General Bill Barr to represent it in court, according to Kevin Sabet, the organization’s president and CEO.
“As we speak, we are preparing to file suit against the administration to block this rule, if it should ever become final,” Sabet said in a video posted to X. And Barr, who led the Justice Department in Trump’s first term, “has assured me we have an excellent case,” Sabet added.
SAM’s argument isn’t known, but observers predict it is likely to challenge rescheduling on procedural grounds and allege that federal administrative law wasn’t obeyed.
That’s the process that dragged on all of last year, after the DEA fielded 43,000 comments from the public on the question, some of which requested the still-paused hearings.
If Bondi goes too far too quickly, all it might take is one unfriendly judge in an obscure district to slap a stay on rescheduling – and delay 280E relief and everything else indefinitely, Cavedon said.
‘You do want this to move fast,’ but…
And there’s a worst-case scenario.
If a federal judge decides the process was bungled and marijuana rescheduling ends up mired in the lawsuits that legalization opponents have vowed to bring, it could be another two or three years before Schedule 3 is a reality, Cavedon added.
That’s why as fast as the industry may want rescheduling to happen, it may be preferable if it’s done carefully – and correctly.
Subscribe to the MJBiz Factbook
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype.
What you will get:
- Monthly and quarterly updates, with new data & insights
- Financial forecasts + capital investment trends
- State-by-state guide to regulations, taxes & market opportunities
- Annual survey of cannabis businesses
- Consumer insights
- And more!
“You do want this to move fast and, frankly, after this many decades, it should,” Cavedon said.
“This shouldn’t be a hard thing, but you do not want to have DOJ make a hasty call and have this held up in court because some judge decided you didn’t do your homework.”
Chris Roberts can be reached at chris.roberts@mjbizdaily.com.
Medical Disclaimer:
The information provided in these blog posts is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. The use of any information provided in these blog posts is solely at your own risk. The authors and the website do not recommend or endorse any specific products, treatments, or procedures mentioned. Reliance on any information in these blog posts is solely at your own discretion.
